Table 3.

The genotypic association results between prostate cancer aggressiveness (tumor staging, Gleason score at diagnosis, and mortality) and the rs1447295 marker among Caucasians in the BPC3

AggressivenessGenotypeCases (%)Controls (%)OR *99% CI P
LCLUCL
Tumor stage (Phet = 0.153) §C, D, or CaP deathCC500 (70.1)4,367 (79.7)Ref.7.56 × 10−6
AC189 (26.5)1,042 (19.0)1.330.941.87
AA24 (3.4)68 (1.3)2.381.294.40
A and BCC2,317 (75.3)4,367 (79.7)Ref.
AC693 (22.5)1,042 (19.0)1.361.111.66
AA67 (2.2)68 (1.3)1.701.132.56
Gleason score (Phet = 0.929) §≥8CC378 (71.9)4,367 (79.7)Ref.8.73 × 10−5
AC134 (25.4)1,042 (19.0)1.310.961.78
AA14 (2.7)68 (1.3)2.121.203.75
<8CC2,153 (74.2)4,367 (79.7)Ref.
AC677 (23.4)1,042 (19.0)1.291.061.59
AA70 (2.4)68 (1.3)1.681.112.53
Mortality (Phet = 0.373) §Metastatic or fatalCC345 (69.1)4,367 (79.7)Ref.9.46 × 10−3
AC134 (26.9)1,042 (19.0)1.090.611.95
AA20 (4.0)68 (1.3)2.871.226.74
Localized and nonfatalCC1,973 (74.8)4,367 (79.7)Ref.
AC602 (22.7)1,042 (19.0)1.380.852.24
AA61 (2.3)68 (1.3)2.080.513.53
  • NOTE: Tumor stage information was missing for 2,171 cases (cases by cohort: 31 ACS-CPSII, 376 ATBC, 329 EPIC, 83 HPFS, 20 MEC, 233 PHS, and 1,099 PLCO); Gleason score was missing for 2,535 cases (cases by cohort: 160 ACS-CPSII, 389 ATBC, 634 EPIC, 73 HPFS, 12 MEC, 168 PHS, and 1,099 PLCO); mortality/metastases information was missing for 2,826 cases (cases by cohort: 31 ACS-CPSII, 371 ATBC, 622 EPIC, 75 HPFS, 404 MEC, 224 PHS, and 1,099 PLCO).

  • * All multinomial logistic regression models were frequency adjusted for age in 5-y intervals, cohort, ethnicity, and country.

  • 99% CI; lower and upper confidence limits.

  • The P value for association from a Wald χ2 test with 4 df.

  • § The P value for the LRT for heterogeneity across prostate cancer aggressiveness with 2 df.